Filing Details
- Accession Number:
- 0001012975-15-000485
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-06-12 16:58:12
- Reporting Period:
- 2015-06-11
- Filing Date:
- 2015-06-12
- Accepted Time:
- 2015-06-12 16:58:12
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1586049 | Oxford Immunotec Global Plc | OXFD | In Vitro & In Vivo Diagnostic Substances (2835) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1249153 | Dennis Henner | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1252522 | Nicholas Galakatos | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1252523 | Robert Liptak | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1252525 | Kurt Wheeler | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1431403 | Nicholas Simon | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1431441 | Clarus Ventures I, Llc | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1431445 | Clarus Lifesciences I, L.p. | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1505590 | Clarus Ventures I Management, L.p. | C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Disposition | 2015-06-11 | 25,168 | $14.27 | 2,285,037 | No | 4 | S | Direct | |
Ordinary Shares | Disposition | 2015-06-12 | 6,430 | $14.25 | 2,278,607 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Securities held of record by Clarus Lifesciences I, L.P. ("Clarus"). Clarus Ventures I Management, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. Clarus Ventures I, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Simon and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of the GPLP, GPLLC and Messrs. Galakatos, Henner, Liptak, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which it or he, as applicable, does not have an actual pecuniary interest.
- The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $14.25 to $14.39 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.